Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry.
about
Biological markers of amyloid beta-related mechanisms in Alzheimer's diseaseThe potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's diseaseQuantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applicationsA window into the heterogeneity of human cerebrospinal fluid Aβ peptidesAlzheimer's disease--a panorama glimpseAmyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation.BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous systemAmyloid-beta isoform metabolism quantitation by stable isotope-labeled kineticsPyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.Highly potent soluble amyloid-β seeds in human Alzheimer brain but not cerebrospinal fluidEffects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease.Amyloid-β metabolism in Niemann-Pick C disease models and patients.Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease.A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer diseaseIdentification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS methodEvaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient.The amyloid-β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's diseaseCharacterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptides.Development of a magnetic immunosorbent for on-chip preconcentration of amyloid β isoforms: Representatives of Alzheimer's disease biomarkersRegulation of presynaptic Ca2+, synaptic plasticity and contextual fear conditioning by a N-terminal β-amyloid fragment.Cerebrospinal Aβ11-x and 17-x levels as indicators of mild cognitive impairment and patients' stratification in Alzheimer's disease.Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluidMagneto-immunocapture with on-bead fluorescent labeling of amyloid-β peptides: towards a microfluidized-bed-based operation.Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls.Second generation γ-secretase modulators exhibit different modulation of Notch β and Aβ production.Targeting the glycoproteomeMass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease.Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice.CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease.Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementiaClinical proteomics in neurodegenerative disorders.Targeted proteomics in Alzheimer's disease: focus on amyloid-beta.Magnetic bead processor for rapid evaluation and optimization of parameters for phosphopeptide enrichment.A facile method for expression and purification of the Alzheimer's disease-associated amyloid beta-peptide.Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathwayThe use of mass spectrometry to study amyloid-β peptides.Cerebrospinal fluid biomarkers for Alzheimer's disease: the present and the future.The proteomic toolbox for studying cerebrospinal fluid.Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.
P2860
Q24622136-ABC04C0F-E799-4C52-AE76-B45DEC80514DQ26853347-03668076-3644-4D4B-BFE9-0486F7A7F2DAQ26995267-32D2FCD9-5FCA-4151-B9CF-8863B0B869F1Q27010785-006FF40F-A6B3-445D-8374-ABFC984F7D8CQ27011749-C54BB390-70E2-4699-869F-7F4922DC8734Q27333145-E5DB3478-D688-4677-931D-3676DEA0E1C2Q28480522-5EC4025C-E5F9-4B00-93F8-B60BFE555ECBQ28681651-FF43F5D5-2D62-412B-9EDA-BB84D817F7EAQ30512697-FCA70BE3-B8E5-4C71-88B9-12DC563383A4Q30842997-5F785B91-3CB4-4BB2-BF7C-C47E388A82CAQ30940227-02B73C3A-B314-4E3D-BB73-BA4C870BCB81Q31088092-C0E1EA81-3267-4F59-880D-D2C352EC4CEDQ33638748-09798CE2-D22B-4CB5-89FC-3FD2AC3D8BEBQ33877903-8AB3ACFC-F953-491C-B314-A1E17ECD79EDQ33933189-ABF35A7E-0CD9-485A-97EC-4FF09581653DQ34149524-17DE317D-9A44-4363-98B3-1C1ED5243F12Q34151493-518DC96F-764B-4A60-9982-718FE1660DBFQ34244772-0703FC45-60F0-42A4-9677-3C45DADF4C32Q34308649-191DA8CE-D483-4E56-9F5D-FBCF4F39BA6EQ34383395-E91E7C27-9F79-4FF1-9006-51BBC08D8728Q34824216-AC91F68E-520F-4DD6-B88B-F9073DDF598FQ35118876-CB67F480-66E4-4A88-B0D7-207D6E36D31AQ35123119-7A7A235F-9564-4802-A464-EB4C6B0B7DCAQ35709581-64FE5219-A678-4345-A020-AF5F20505042Q35806251-00ED9156-5FA6-4FDF-BA9D-5F7BC3DA9DF8Q36294856-5D95C5F9-E8DC-4B1A-9BEC-905F2F4E789CQ36554714-26502A03-0B52-4EB8-8293-41FEA22F5C7FQ36600041-B79D26FC-ADED-4553-89DD-4CD2ED755580Q36614269-F7CDDB65-4EFC-4C13-8458-86A6D905B763Q36639655-80EB87A7-FF92-4342-9D33-11A59A129AF6Q36708123-C96F424C-4BE0-4A93-912A-64DC5D040100Q37086170-92377383-6FEA-44EE-B921-FB6B6E345FE5Q37157835-AF15A150-C339-4D50-8F19-4BABE2B17996Q37215844-C797BDCD-F1D2-4FC4-A0CC-071ADF7F86D6Q37242843-6BE5F417-EB2E-4850-8822-93FC73910894Q37652424-0DDF5AA9-B748-4EFD-9DC7-D4F20135369DQ37866222-D2ED1221-10B3-46BD-9CB5-0B04F5D2FE9AQ37895052-255FF93A-E748-4711-ADC5-E8DCC546C2EBQ37998531-F79892B5-344A-4D10-B9C1-7238209DF32CQ38210117-8367F8DB-6C54-41B9-A242-C407509E7865
P2860
Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Characterization of amyloid be ...... followed by mass spectrometry.
@ast
Characterization of amyloid be ...... followed by mass spectrometry.
@en
Characterization of amyloid be ...... followed by mass spectrometry.
@nl
type
label
Characterization of amyloid be ...... followed by mass spectrometry.
@ast
Characterization of amyloid be ...... followed by mass spectrometry.
@en
Characterization of amyloid be ...... followed by mass spectrometry.
@nl
prefLabel
Characterization of amyloid be ...... followed by mass spectrometry.
@ast
Characterization of amyloid be ...... followed by mass spectrometry.
@en
Characterization of amyloid be ...... followed by mass spectrometry.
@nl
P2093
P50
P356
P1476
Characterization of amyloid be ...... followed by mass spectrometry.
@en
P2093
Ai Jun Tran
Rita Persson
Ulf Andreasson
P304
P356
10.1021/PR0703627
P577
2007-10-10T00:00:00Z